S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:LEGN

Legend Biotech Stock Forecast, Price & News

$51.91
+0.16 (+0.31 %)
(As of 10/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$50.84
$52.48
50-Day Range
$35.31
$56.98
52-Week Range
$23.41
$58.00
Volume308,848 shs
Average Volume424,342 shs
Market Capitalization$7.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.15
30 days | 90 days | 365 days | Advanced Chart
Receive LEGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.


Legend Biotech logo

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Headlines

Legend Biotech (NASDAQ:LEGN) Shares Down 4.5%
October 13, 2021 |  americanbankingnews.com
Legend Biotech (NASDAQ:LEGN) Stock Price Up 7% on Analyst Upgrade
October 11, 2021 |  americanbankingnews.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Analyst Upgrade
October 8, 2021 |  americanbankingnews.com
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $65.00
October 8, 2021 |  americanbankingnews.com
Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month High at $54.85
October 6, 2021 |  americanbankingnews.com
Legend Biotech (NASDAQ:LEGN) Sets New 52-Week High at $50.12
September 30, 2021 |  americanbankingnews.com
Legend Biotech to Host R&D Day on October 18, 2021
September 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LEGN
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$75.68 million
Book Value
$2.17 per share

Profitability

Net Income
$-303.48 million
Net Margins
-343.40%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$7.51 billion
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

1008th out of 1,361 stocks

Pharmaceutical Preparations Industry

488th out of 668 stocks

Analyst Opinion: 2.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Legend Biotech (NASDAQ:LEGN) Frequently Asked Questions

Is Legend Biotech a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Legend Biotech stock.
View analyst ratings for Legend Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Legend Biotech?

Wall Street analysts have given Legend Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Legend Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Legend Biotech's next earnings date?

Legend Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Legend Biotech
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) posted its quarterly earnings data on Sunday, August, 22nd. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.30. The business earned $20.23 million during the quarter, compared to analysts' expectations of $12.50 million. Legend Biotech had a negative net margin of 343.40% and a negative trailing twelve-month return on equity of 101.68%.
View Legend Biotech's earnings history
.

What price target have analysts set for LEGN?

3 analysts have issued 1 year target prices for Legend Biotech's shares. Their forecasts range from $51.00 to $65.00. On average, they expect Legend Biotech's stock price to reach $58.00 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price.
View analysts' price targets for Legend Biotech
or view top-rated stocks among Wall Street analysts.

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Dr. Ying Huang, CEO & CFO (Age 48)
  • Dr. Frank Fan M.D., Ph.D., Co-Founder & Chief Scientific Officer
  • Jessie Yeung, Head of Corp. Fin. & Investor Relations
  • Deborah Wong, Exec. Director of Strategic Marketing & Corp. Communications
  • Dr. Meeta Chatterjee Ph.D., Sr. VP of Global Bus. Devel. (Age 66)
  • Ms. Liz Gosen, Sr. VP of Global Technical Operations
  • Surabhi Verma, Mang. of Investor Relations & Corp. Communications

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

(LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."

How do I buy shares of Legend Biotech?

Shares of LEGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Legend Biotech's stock price today?

One share of LEGN stock can currently be purchased for approximately $51.91.

How much money does Legend Biotech make?

Legend Biotech has a market capitalization of $7.51 billion and generates $75.68 million in revenue each year. The company earns $-303.48 million in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does Legend Biotech have?

Legend Biotech employs 2,020 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is www.legendbiotech.com.

Where are Legend Biotech's headquarters?

Legend Biotech is headquartered at 2101 COTTONTAIL LANE, SOMERSET NJ, 08873.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The company can be reached via phone at 732-317-5050 or via email at [email protected].


This page was last updated on 10/17/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.